Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker TVGN, is a clinical-stage biopharmaceutical company that reached the public markets through a SPAC business combination and operates in the biotechnology and immunology sector, with a focus on T-cell-based therapeutic candidates targeting infectious diseases and oncology. The company filed an 8-K with the SEC on February 25, 2026, bearing accession number 0001493152-26-008065, reflecting an ongoing disclosure obligation as a post-combination public registrant. TVGN continues to carry the reporting structure common to de-SPAC companies navigating the clinical-stage pipeline and regulatory pathway. For comprehensive filing history, sponsor details, and SPAC transaction data on TVGN, sign up for full access at SpacDesk.